[
  {
    "ts": "2025-12-03T05:11:05+00:00",
    "headline": "Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards",
    "summary": "Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied to a review of reported child fatalities following COVID 19 vaccinations. See our latest analysis for Moderna. That 6% drop sits on top of a steep year to date share price return of around negative 43%, and with one year total shareholder return also down sharply, it suggests sentiment is still fragile and recent momentum is fading despite episodic regulatory and...",
    "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-fda-051105671.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "6620935f-cdd4-3cc3-8237-e62199cbc5e8",
      "content": {
        "id": "6620935f-cdd4-3cc3-8237-e62199cbc5e8",
        "contentType": "STORY",
        "title": "Moderna (MRNA): Reassessing Valuation After FDA Signals Tougher Vaccine Approval Standards",
        "description": "",
        "summary": "Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied to a review of reported child fatalities following COVID 19 vaccinations. See our latest analysis for Moderna. That 6% drop sits on top of a steep year to date share price return of around negative 43%, and with one year total shareholder return also down sharply, it suggests sentiment is still fragile and recent momentum is fading despite episodic regulatory and...",
        "pubDate": "2025-12-03T05:11:05Z",
        "displayTime": "2025-12-03T05:11:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-fda-051105671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-fda-051105671.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]